公开(公告)号：US20180311372A1

公开(公告)日：2018-11-01

申请号：US15872841

申请日：2018-01-16

Applicant: AMGEN INC.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle VENIANT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K47/68 ,  C07K16/28 ,  A61P3/10

CPC classification number: C07K16/28 ,  A61K39/395 ,  A61P3/10

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20250121056A1

公开(公告)日：2025-04-17

申请号：US18982197

申请日：2024-12-16

Applicant: AMGEN INC.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle M. VENIANT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K39/395 ,  A61K47/68 ,  A61P3/10 ,  C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20210154318A1

公开(公告)日：2021-05-27

申请号：US17151045

申请日：2021-01-15

Applicant: Amgen Inc.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle VENIENT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K47/68 ,  A61P3/10 ,  C07K16/28 ,  A61K39/395

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20210108212A1

公开(公告)日：2021-04-15

申请号：US17080771

申请日：2020-10-26

Applicant: AMGEN INC.

Inventor： Michael OLLMANN ,  Yang LI ,  Jun ZHANG ,  Kaustav BISWAS ,  Oliver HOMANN ,  Leslie P. MIRANDA ,  Justin K. MURRAY ,  Bin WU ,  Oh Kyu YOON ,  John Gordon ALLEN ,  Chawita NETIROJJANAKUL ,  Yuan CHENG

IPC: C12N15/113 ,  A61P9/10 ,  A61P3/06 ,  C07K16/28

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

公开(公告)号：US20190309306A1

公开(公告)日：2019-10-10

申请号：US16328221

申请日：2017-08-25

Applicant: AMGEN INC.

Inventor： Michael OLLMANN ,  Yang LI ,  Jun ZHANG ,  Kaustav BISWAS ,  Oliver HOMANN ,  Leslie P. MIRANDA ,  Justin K. MURRAY ,  Bin WU ,  Oh Kyu YOON ,  John Gordon ALLEN ,  Chawita NETIROJJANAKUL ,  Yuan CHENG

IPC: C12N15/113 ,  A61P3/06 ,  A61P9/10 ,  C07K16/28

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.